Search Results
Your search for Harry D. Bear, MD, PhD,Harry D. Bear, MD, PhD matches 5 pages
Showing 1 - 5
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive...
Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract PD2-1, “The effect on overall and disease-free survival by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40.”
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials: • B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab• B-51, on radiation to the chest wall• Alliance trial, on lymph node dissection
Breast Cancer Studies Focus on Tailoring Therapy for Patient Subsets
As part of our ongoing coverage of the 2011 ASCO Annual Meeting, The ASCO Post has provided substantive reports on key breast cancer trials, but others deserve attention. Lapatinib/Capecitabine Controls Brain Metastases Results of the French phase II LANDSCAPE trial found lapatinib (Tykerb) plus...
Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early HER2-Negative Breast Cancer
The phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel + anthracycline-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early...
